Stock Events

Stock Events

Neurocrine Biosciences 

€146.45
223
-€0.75-0.51%Friday 16:30

Statistics

Day High
144.85
Day Low
141.95
52W High
149.9
52W Low
121.05
Volume
-
Avg. Volume
-
Mkt Cap
14.89B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Feb 11Expected
Q2 2026
Q3 2026
Next
1.21
1.42
1.64
1.85
Expected EPS
1.853866868
Actual EPS
N/A

Financials

16.48%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
2.48BRevenue
407.98MNet Income

Analyst Ratings

$158.19Average Price Target
The highest estimate is ⁦191.98⁩.
From 17 ratings within the last 6 months. This is not an investment recommendation.
Buy
88%
Hold
12%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NB3.XETRA. It's not an investment recommendation.
NVIDIA
60
NVDA
Microsoft
53
MSFT
Amazon
51
AMZN
Alphabet
47
GOOGL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie competes in the neurology and psychiatry market, particularly with treatments for Parkinson's disease, directly competing with Neurocrine's offerings.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap49.09B
Teva Pharmaceutical has a strong focus on CNS (Central Nervous System) disorders, including treatments for movement disorders, making it a direct competitor.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.55B
Acadia Pharmaceuticals offers products for CNS disorders, including Parkinson’s disease psychosis, competing in Neurocrine's market space.
Alkermes
ALKS
Mkt Cap7.61B
Alkermes competes in the area of CNS disorders, with a focus on schizophrenia and bipolar disorder, overlapping with Neurocrine's psychiatric disorder treatments.
AMGEN
AMGN
Mkt Cap251.94B
Amgen has a broad portfolio that includes treatments for neurological disorders, potentially competing with Neurocrine's neurology-focused therapies.
Biogen
BIIB
Mkt Cap37.49B
Biogen focuses on neurology, with treatments for multiple sclerosis and spinal muscular atrophy, indicating a competitive overlap in the neurology space.
Merck
MRK
Mkt Cap368.89B
Merck & Co., Inc. has a diversified portfolio that includes treatments for neurological conditions, potentially competing with Neurocrine.
Pfizer
PFE
Mkt Cap173.95B
Pfizer has a broad range of treatments, including for neurological conditions, making it a competitor in the neurology and psychiatry market.

About

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Show More
CEO
Kyle W. Gano
Employees
2500
Country
United States
ISIN
US64125C1099
WKN
000900964

Listings

MI
IT
1NBIX.MI
XNAS
US
NBIX
STU
DE
NB3.STU
SA
BR
N1BI34.SA

0 Comments

Share your thoughts

FAQs

What is Neurocrine Biosciences stock price today?▼
The current price of NB3.XETRA is €146.45 EUR — it has decreased by -0.51% in the past 24 hours. Watch Neurocrine Biosciences stock price performance more closely on the chart.
What is Neurocrine Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XETRA Stock Exchange exchange Neurocrine Biosciences stocks are traded under the ticker NB3.XETRA.
What is Neurocrine Biosciences market cap?▼
Today Neurocrine Biosciences has the market capitalization of 14.89B
When is the next Neurocrine Biosciences earnings date?▼
Neurocrine Biosciences is going to release the next earnings report on February 11, 2027.
What were Neurocrine Biosciences earnings last quarter?▼
NB3.XETRA earnings for the last quarter are 1.75 EUR per share, whereas the estimation was 1.71 EUR resulting in a +2.62% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Neurocrine Biosciences revenue for the last year?▼
Neurocrine Biosciences revenue for the last year amounts to 2.48B EUR.
What is Neurocrine Biosciences net income for the last year?▼
NB3.XETRA net income for the last year is 407.98M EUR.
How many employees does Neurocrine Biosciences have?▼
As of November 8, 2026, the company has 2,500 employees.
In which sector is Neurocrine Biosciences located?▼
Neurocrine Biosciences operates in the Health & Wellness sector.
When did Neurocrine Biosciences complete a stock split?▼
Neurocrine Biosciences has not had any recent stock splits.
Where is Neurocrine Biosciences headquartered?▼
Neurocrine Biosciences is headquartered in SAN DIEGO, United States.